A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 09 Aug 2016
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Aug 2013 Primary endpoint 'Disease-free-survival-duration' has not been met.
- 26 Aug 2013 Results published in the Journal of Clinical Oncology.
- 09 Jan 2012 Official Title amended as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History